Further disorders which may be treated according to the present invention include psychiatric disorders (such as schizophrenia) and neurodegenerative diseases such as Alzheimer's disease, Parkinson'sdisease and Huntington's disease.The compounds of the invention are antagonists at NMDA receptor sites in the CNS and show greater potency when compared to compounds of the prior art.